Abstract:IntroductionDNA replication is initiated by assembling pre-replicative complex (pre-RC), and DNA replicative protein Cdc6 plays a central role in the initiation of DNA replication.As cells enter G1 from mitosis, Cdc6, together with Cdt1 are recruited to the replicating origins bound with six components of origin recognition complex (ORC) (Dutta and Bell, 1997; Méndez and Stillman, 2000).The pre-RC is formed by loading minichromosome maintenance proteins (MCMs) along with other replicating proteins onto origins, and Cdc6 controls the loading.The stability of Cdc6 during G1 is a key step to regulate pre-RC assembly.Cdc6 is targeted to ubiquitin-mediated proteolysis by the anaphase promoting complex (APC) in G1.The cyclindependent kinase (CDK), specifically, cyclin E-Cdk2 kinase is responsible for phosphorylation of human Cdc6, and Cdc6 is stabilized with its amino-terminal end phosphorylated (Mailand and Diffley, 2005).The Cdc6 phosphorylation by CDKs ensures that origin is fired at S phase, and DNA is replicated only once per S phase.Human Cdc6 is also involved in G2/M phase checkpoint as overexpression of Cdc6 in G2 blocks HeLa cell into mitosis (Clay-Farrace et al., 2003).More recently, human Cdc6 shows to play a role in late S phase and S-G2/M transition in controlling cell cycle progression (Lau et al., 2006).These studies suggest that human Cdc6 functions beyond its essential role in the initiation of DNA replication.Senescence is an irreversible cell event with permanent G1 arrest.Senescent normal somatic cells show features such as the permanent arrest of proliferation, repression of telomerase reverse transcriptase (TERT) expression, and expression of senescence associated-βgalactosidase (SA-β-Gal).The lack of TERT activities has been observed in most human somatic cells and is linking to replicative senescence (Campisi, 2001).Replicative senescence occurs with functional p53 and p16 INK4a -Rb pathway (Campisi, 2001;Beauséjour et al., 2003).Accumulated evidence shows that tumor cells experience p53 mutation, p16 INK4a or Rb inactivation or deletion, accompanied with the re-expression of TERT.Evidence shows that senescence normal fibroblasts undergo the formation of senescence-associated heterochromatic foci (SAHF), and tri-or di-methylation of lysine 9 on histone H3 (H3K9me3/me2) has been found in the SAHF (Narita et al., 2003(Narita et al., , 2006)). www.intechopen.comFundamental Aspects of DNA Replication 108 High level of Cdc6 has been associated with the oncogenic activities in human cancers, and there is a reciprocal association in protein levels between Cdc6 and p16 INK4a (Gonzalez et al., 2006).Genetically, human Cdc6 suppresses p16 INK4a functions.Cdc6 shows dual effects on the INK4/ARF locus: it associates with the replication origin on chromatin together with ORCs for loading MCM proteins, and it binds a region called regulatory domain (RD INK4/ARF ) in the putative replication origin.This association results in transcriptional repression of the three genes encoding for p15 INK4b , p16 INK4a , and p14 ARF , leading to heterochromatinization of the INK4/ARF locus (Gonzalez et al., 2006).The gene products from the INK4/ARF locus are thought as barries to immortalization and oncogenesis.p16 INK4a inhibits D-type cyclins-Cdk4/Cdk6 kinases, which activates p16 INK4a -Rb pathway in controlling cell cycle progression. Cdc6 is a decisive factor in promoting cell proliferationCdc6 is essential in the initiation of DNA replication.Human Cdc6 function is of importance in cell cycle progression and cell proliferation.In human cells, the levels of Cdc6 change markedly in response to various stresses.DNA re-replication has been found in those Cdc6 and Cdt1 overexpressing normal or tumor cells.Cdc6 could be more stable in tumor cells, due to p53 deficiency, and due to strong Cdc6 phosphorylation by activated cyclin E-Cdk2 kinase (Bartkova et al.,

CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts

CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts

CDK1 Promotes Nascent DNA Synthesis and Induces Resistance of Cancer Cells to DNA-damaging Therapeutic Agents.

Role of specific CDKs in regulating DNA damage repair responses and replication stress

DNA Damage Checkpoint Recovery and Cancer Development

Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma

CDK12: A Potent Target and Biomarker for Human Cancer Therapy

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13

Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors

Targeted Degradation of CDK9 Potently Disrupts the MYC Transcriptional Network

Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets

Oncogenic c-Myc induces replication stress by increasing cohesins chromatin occupancy in a CTCF-dependent manner

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

CDK12‐inactivation‐induced MYC signaling causes dependency on the splicing kinase SRPK1

Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.

Abstract 5608: The BRCA1-associated role of CDK9 in response to DNA damage is independent of its canonical role in transcription

CDK9-55 guides the anaphase-promoting complex/cyclosome (APC/C) in choosing the DNA repair pathway choice

Cdt1 revisited: complex and tight regulation during the cell cycle and consequences of deregulation in mammalian cells

Replication Licensing Promotes Cyclin D1 Expression and G1progression in Untransformed Human Cells

Cdc6 Knockdown Renders P16ink4a Re-Activation, Leading to Senescence Human Breast Carcinoma Cells

Compromised CDK12 activity causes dependency on the high activity of O-GlcNAc transferase